Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
PEN · NYSE · United States · Surgical & Medical Instruments & Apparatus
In shortPenumbra Inc is profitable.
Financial health
Strong
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 13.5% | 62/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 12.7% | 71/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 13.8% | 69/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 6.64× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | n/a |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 144.35× | 100/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 8.59 | 100/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 12.5% | 70/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 0.98× | 86/100 |
| Years with positive free cash flow (last 5) | 3 of 5 | 50/100 |
Weight in the score: 20%
| Profitable years (last 5) | 4 of 5 | 80/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 8.7% | 79/100 |
| Operating margin volatility | 6.0% | 54/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 18.3% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 748 | 847 | 1,059 | 1,195 | 1,404 |
| Cost of revenue | 272 | 312 | 376 | 440 | 461 |
| Gross profit | 475 | 535 | 683 | 755 | 942 |
| Research & development | 105 | 79 | 84 | 95 | 90 |
| Selling, general & admin | 378 | 450 | 506 | 574 | 663 |
| Operating income | (7.5) | 6.1 | 74 | 9.3 | 189 |
| Interest expense | 1.9 | 1.7 | 1.7 | 1.4 | 1.3 |
| Pre-tax income | (11) | 3.9 | 80 | 21 | 205 |
| Income tax | (13) | 5.9 | (11) | 6.9 | 27 |
| Net income | 5.3 | (2) | 91 | 14 | 178 |
| Diluted EPS | $0.14 | −$0.05 | $2.32 | $0.36 | $4.52 |
| Diluted shares (millions) | 38 | 38 | 39 | 39 | 39 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
8.59 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
8/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Jul 30, 2026